Myriad Genetics, Inc. (
F2Q12 Earnings Call
January 31, 2012 04:30 p.m. ET
Peter D. Meldrum – President and CEO
Mark C. Capone – President, Myriad Genetic Laboratories
James S. Evans – CFO
Rebecca Chambers – Director of IR
Amanda Murphy - William Blair & Company
Jon Wood – Jefferies & Company
Scott Gleason - Stephens Inc.
Michael Yee - RBC Capital Markets
Doug Schenkel - Cowen & Co.
Tycho Peterson – JP Morgan
Isaac Ro - Goldman Sachs & Co.
William Quirk - Piper Jaffray
Dan Leonard - Leerink Swann
Peter Lawson - Mizuho Securities USA Inc.
Ladies and gentlemen, thank you for standing by. Welcome to Myriad Genetics’ Fiscal Second Quarter Earnings Call. (Operator instructions) As a reminder, this conference is being recorded Tuesday, January 31, 2012.
I would now like to turn the conference over to Rebecca Chambers, Director of Investor Relations. Please go ahead, ma’am.
Thank you, Lindsey. Good afternoon everyone, and welcome to the Myriad Genetics’ Second Fiscal Quarter Earnings Call. During the call we will review the financial results we released today and the progress we have made this quarter on our strategic directives, after which we will host a question-and-answer session. If you have not had a chance to review the earnings release it can be found in the Investor Relations section of our website at www.myriad.com.
Presenting from Myriad today will be Pete Meldrum, President and Chief Executive Officer; Mark Capone, President, Myriad Genetic Laboratories; and Jim Evans, Chief Financial Officer. This call can be heard live via webcast along with the slide presentation at www.myriad.com. The call is being recorded and will be archived along with the presentation in the Investor section of our website.